Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for the treatment of diabetes

Inactive Publication Date: 2001-12-11
TAKEDA PHARMACEUTICA CO LTD
View PDF8 Cites 69 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

(21) a method for reducing the amount of an insulin sensitizer or / and an anorectic administered to a diabetic mammal, which comprises administering to said mammal an effective amount of them.
Further, use of a pharmaceutical composition of the present invention in combination with insulin secretion enhancers, biguanides, .alpha.-glucosidase inhibitors, and etc. provides a more excellent blood sugar lowering effect.

Problems solved by technology

However, observance and continuation of the alimentotherapy is accompanied by mental pains of patients, and in many cases does not provide the expected results.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the treatment of diabetes
  • Pharmaceutical composition for the treatment of diabetes
  • Pharmaceutical composition for the treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

reference example 2

In the similar manner to Reference Example 1, 140000 tablets having the following composition and each containing 30 mg of pioglitazone were obtained.

reference example 3

In the similar manner to Reference Example 2, 140000 tablets having the following composition and each containing 45 mg of pioglitazone were obtained.

example 1

Effects of concomitant administration of pioglitazone hydrochloride and mazindol in noninsulin-dependent diabetic mellitus (NIDDM) patients were studied.

When pioglitazone hydrochloride (45 mg / day, oral administration) was concomitantly administered to a NIDDM patient [one sample(man); 44 years old; body weight 99.0 kg; fasting blood sugar 242.0 mg / dl; HbA.sub.1c 11.0%] under treatment with mazindol (1.0 mg / day, oral administration) over the period of 8 weeks, fasting blood sugar decreased by 70.0 mg / dl, HbA.sub.1c decreased by 2.00%, and body weight decreased by 1.00 kg.

When placebo (oral administration) was administered to NIDDM patients [55 samples (20 men and 35 women); 37 to 73 years old (57.9.+-.8.7 (means.+-.standard deviation) years old; body weight 59.8.+-.12.1 (means.+-.standard deviation of 54 samples) kg; fasting blood sugar 180.1 .+-.23.0 (means.+-.standard deviation) mg / dl; HbA.sub.1c 8.8.+-.1.3 (means.+-.standard deviation) %] over the period of 12 .+-.2 weeks, fasting...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

Description

The present invention relates to a pharmaceutical composition which comprises an insulin sensitizer (insulin resistance-improving agent) in combination with an anorectic. The pharmaceutical composition of the present invention can be used as an agent for preventing or treating diabetes, etc.Examples of prior art references which relate to an insulin sensitizer or an anorectic are mentioned below.1) JP-A H9(1997)-67271 describes "a pharmaceutical composition an insulin sensitivity enhancer in combination with at least one member selected from the group consisting of .alpha.-glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a statin compound, a squalene synthesis inhibitor, a fibrate compound, a LDL catabolism enhancer and an angiotensin converting enzyme inhibitor".2) JP-A H5(1993)-148196 describes that "a pharmaceutical composition comprising 4-[2-(2-hydroxy-2-phenylethylamino)ethoxy]phenyl acetic acid, or its precursor or its pharmaceutically acceptable salt and a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K45/06A61K31/425A61K31/44A61K31/421A61K31/426A61K31/4439
CPCA61K31/425A61K31/44A61K45/06A61K31/415A61K2300/00Y10S514/866A61P3/10
Inventor ODAKA, HIROYUKIYAMANE, MASAHIRO
Owner TAKEDA PHARMACEUTICA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com